Keyword: Mayzent (siponimod)
A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.
Novartis is working to change doctors’ “psychology” around SPMS treatment. And new disability data for its drug, Mayzent, should help its case.
Patients on Ocrevus saw their blood neurofilament light chain level lowered to a healthy donor range in phase 3 studies, Roche said.
ICER has ruled that neither Novartis' $88,500 MS drug Mayzent nor J&J's $32,400 depression spray Spravato is cost effective.
New analysis found Mayzent had meaningful benefits on cognitive processing speed in patients with secondary progressive multiple sclerosis.
Novartis officially has approval for Mayzent to treat patients with secondary progressive multiple sclerosis.
Novartis hopes its MS drug siponimod’s performance can help secure a blockbuster approval. And now it has more data to back it up.
Novartis’ multiple sclerosis pill Gilenya may soon be in trouble on the generics front. But the Swiss drugmaker has another MS product in the works that it thinks could break the billion-dollar sales mark.